Brokerages Set Alto Neuroscience, Inc. (NYSE:ANRO) PT at $23.83

by · The Cerbat Gem

Alto Neuroscience, Inc. (NYSE:ANRO – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the eight ratings firms that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, five have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $23.8333.

Several equities research analysts recently issued reports on ANRO shares. Chardan Capital upgraded shares of Alto Neuroscience to a “strong-buy” rating in a research report on Wednesday, November 19th. Wall Street Zen raised shares of Alto Neuroscience from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. BTIG Research assumed coverage on Alto Neuroscience in a research report on Monday, November 17th. They issued a “buy” rating and a $27.00 price objective for the company. Robert W. Baird lifted their target price on Alto Neuroscience from $16.00 to $22.00 and gave the company an “outperform” rating in a research report on Thursday, November 13th. Finally, HC Wainwright increased their price target on Alto Neuroscience from $10.00 to $50.00 and gave the stock a “buy” rating in a report on Friday, October 24th.

View Our Latest Stock Report on ANRO

Alto Neuroscience Trading Down 2.0%

Alto Neuroscience stock opened at $19.65 on Friday. Alto Neuroscience has a 12 month low of $1.60 and a 12 month high of $20.91. The company has a current ratio of 15.42, a quick ratio of 15.42 and a debt-to-equity ratio of 0.20. The stock’s 50 day simple moving average is $13.40 and its two-hundred day simple moving average is $6.93. The firm has a market cap of $610.46 million, a PE ratio of -8.58 and a beta of 2.95.

Alto Neuroscience (NYSE:ANRO – Get Free Report) last posted its earnings results on Wednesday, November 12th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.66) by $0.14. Analysts anticipate that Alto Neuroscience will post -2.54 earnings per share for the current year.

Institutional Trading of Alto Neuroscience

Institutional investors have recently bought and sold shares of the business. Armistice Capital LLC grew its position in shares of Alto Neuroscience by 146.2% in the 1st quarter. Armistice Capital LLC now owns 1,600,000 shares of the company’s stock valued at $3,456,000 after buying an additional 950,000 shares during the last quarter. Peapod Lane Capital LLC acquired a new stake in shares of Alto Neuroscience during the second quarter worth about $613,000. AWM Investment Company Inc. boosted its position in shares of Alto Neuroscience by 31.1% in the 1st quarter. AWM Investment Company Inc. now owns 901,984 shares of the company’s stock valued at $1,948,000 after purchasing an additional 214,153 shares during the period. Nuveen LLC purchased a new position in Alto Neuroscience during the 1st quarter worth approximately $302,000. Finally, Jane Street Group LLC acquired a new position in Alto Neuroscience during the second quarter worth approximately $240,000.

Alto Neuroscience Company Profile

(Get Free Report)

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.

Read More